{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:17:10Z","timestamp":1761621430240,"version":"3.37.3"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["PEst C-QUI\/UI0062\/2019"],"award-info":[{"award-number":["PEst C-QUI\/UI0062\/2019"]}]},{"name":"Fundo Europeu de Deselvolvimento Regional","award":["FCOMP-01-0124-FEDER-037296"],"award-info":[{"award-number":["FCOMP-01-0124-FEDER-037296"]}]},{"name":"Programa Compete","award":["FCOMP-01-0124-FEDER-037296"],"award-info":[{"award-number":["FCOMP-01-0124-FEDER-037296"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Incl Phenom Macrocycl Chem"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10847-019-00885-y","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T15:46:42Z","timestamp":1549295202000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treating an old disease with new tricks: strategies based on host\u2013guest chemistry for leishmaniasis therapy"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-970X","authenticated-orcid":false,"given":"Susana","family":"Santos Braga","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"885_CR1","unstructured":"World Health Organization (WHO): Leishmaniasis\u2014situation and trends. Global Health Observatory (GHO) data, http:\/\/www.who.int\/gho\/neglected_diseases\/leishmaniasis\/en\/ (2015). Accessed 11 Oct 2018"},{"key":"885_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1574-695X.2008.00455.x","volume":"54","author":"FF Tuon","year":"2008","unstructured":"Tuon, F.F., Neto, V.A., Amato, V.S.: Leishmania: origin, evolution and future since the Precambrian. FEMS Immun. Med. Microb. 54, 158\u2013166 (2008)","journal-title":"FEMS Immun. Med. Microb."},{"key":"885_CR3","first-page":"289","volume-title":"The Lost City of the Monkey God","author":"D Preston","year":"2017","unstructured":"Preston, D.: We became orphans, oh my sons! In: The Lost City of the Monkey God, pp.\u00a0289\u2013302. London, Head of Zeus Ld (2017)"},{"key":"885_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/835910","author":"IA Rodrigues","year":"2015","unstructured":"Rodrigues, I.A., Mazotto, A.M., Cardoso, V., Alves, R.L., Amaral, A.C.F., Silva, J.R.A., Pinheiro, A.S., Vermelho, A.B.: Natural products: insights into leishmaniasis inflammatory response. Mediat. Inflamm. (2015). https:\/\/doi.org\/10.1155\/2015\/835910","journal-title":"Mediat. Inflamm."},{"key":"885_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"E Torres-Guerrero","year":"2017","unstructured":"Torres-Guerrero, E., Quintanilla-Cedillo, M.R., Ruiz-Esmenjaud, J.: Leishmaniasis: a review. F1000Research 6, 15 (2017)","journal-title":"F1000Research"},{"key":"885_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","volume":"10","author":"D Steverding","year":"2017","unstructured":"Steverding, D.: The history of leishmaniasis. BMC Parasit. Vect. 10, 82 (2017)","journal-title":"BMC Parasit. Vect."},{"key":"885_CR7","doi-asserted-by":"publisher","first-page":"e0004545","DOI":"10.1371\/journal.pntd.0004545","volume":"10","author":"R Du","year":"2016","unstructured":"Du, R., Hotez, P.J., Al-Salem, W.S., Acosta-Serrano, A.: Old World cutaneous leishmaniasis and refugee crisis in the Middle East and North Africa. Plos Negl. Trop. Dis. 10, e0004545 (2016)","journal-title":"Plos Negl. Trop. Dis."},{"key":"885_CR8","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3201\/eid2010.140288","volume":"20","author":"M Saroufim","year":"2014","unstructured":"Saroufim, M., Charafeddine, K., Issa, G., Khalifeh, H., Habib, R.H., Berry, A., Ghosn, N., Rady, A., Khalifeh, I.: Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg. Infect. Dis. 20, 1712\u20131725 (2014)","journal-title":"Emerg. Infect. Dis."},{"key":"885_CR9","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1371\/journal.pntd.0000585","volume":"4","author":"C Gonz\u00e1lez","year":"2010","unstructured":"Gonz\u00e1lez, C., Wang, O., Strutz, S.E., Gonz\u00e1lez-Salazar, C., S\u00e1nchez-Cordero, V., Sarkar, S.: Climate change and risk of leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species. PLoS Negl. Trop. Dis. 4, e585 (2010)","journal-title":"PLoS Negl. Trop. Dis."},{"key":"885_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tmaid.2014.09.007","volume":"12","author":"P Mansueto","year":"2014","unstructured":"Mansueto, P., Seidita, A., Vitale, G., Cascio, A.: Leishmaniasis in travellers: a literature review. Travel Med. Infect. Dis. 12, 563\u2013581 (2014)","journal-title":"Travel Med. Infect. Dis."},{"key":"885_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1590\/S0074-02762007000500001","volume":"102","author":"J Shaw","year":"2007","unstructured":"Shaw, J.: The leishmaniases\u2014survival and expansion in a changing world. A mini-review. Mem. Inst. Oswaldo Cruz. 102, 541\u2013547 (2007)","journal-title":"Mem. Inst. Oswaldo Cruz."},{"issue":"Suppl, I","key":"885_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1590\/S0074-02762003000900029","volume":"98","author":"E Martinson","year":"2003","unstructured":"Martinson, E., Reinhard, K.J., Buikstra, J.E., de la Cruz, K.D.: Pathoecology of Chiribaya parasitism. Mem. Inst. Oswaldo Cruz 98(Suppl, I), 195\u2013205 (2003)","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"885_CR13","unstructured":"Global Health \u2013 Division of Parasitic Diseases: Parasites \u2013 Leishmaniasis. Resources for Health Professionals. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/parasites\/leishmaniasis\/health_professionals\/index.html (2017). Accessed 15 Oct 2018"},{"key":"885_CR14","first-page":"1455","volume":"69","author":"WH Markle","year":"2004","unstructured":"Markle, W.H., Makhoul, K.: Cutaneous leishmaniasis: recognition and treatment. Am. Fam. Physician 69, 1455\u20131460 (2004)","journal-title":"Am. Fam. Physician"},{"key":"885_CR15","unstructured":"World Health Organization (WHO): Leishmaniasis key facts. WHO, http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis (2018). Accessed 16 Oct 2018"},{"key":"885_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3389\/fimmu.2017.01492","volume":"8","author":"R Kumar","year":"2017","unstructured":"Kumar, R., Chauan, S.B., Ng, S.S., Sundar, S., Engwerda, C.R.: Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Front. Immunol. 8, 1492 (2017)","journal-title":"Front. Immunol."},{"key":"885_CR17","doi-asserted-by":"publisher","first-page":"e0005706","DOI":"10.1371\/journal.pntd.0005706","volume":"11","author":"GAS Romero","year":"2017","unstructured":"Romero, G.A.S., Costa, D.L., Costa, C.H.N., de Almeida, R.P., de Melo, E.V., de Carvalho, S.F.G., Rabello, A., de Carvalho, A.L., Sousa, A.Q., Leite, R.D., Lima, S.S., Amaral, T.A., Alves, F.P., Rode, J.: Collaborative LVBrasil group: efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. Plos Negl. Trop. Dis. 11, e0005706 (2017)","journal-title":"Plos Negl. Trop. Dis."},{"key":"885_CR18","doi-asserted-by":"publisher","first-page":"e0005391","DOI":"10.1371\/journal.pntd.0005391","volume":"11","author":"P Saha","year":"2017","unstructured":"Saha, P., Ganguly, S., Chatterjee, M., Das, S.B., Kundu, P.K., Guha, S.K., Ghosh, T.K., Bera, D.K., Basu, N., Maji, A.K.: Asymptomatic leishmaniasis in kala-azar endemic areas of Malda district, West Bengal, India. PLoS Negl. Trop. Dis. 11, e0005391 (2017)","journal-title":"PLoS Negl. Trop. Dis."},{"key":"885_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0041-008X(78)90188-6","volume":"44","author":"RR Hendrixson","year":"1978","unstructured":"Hendrixson, R.R., Mack, M.P., Palmer, R.A., Ottolenghi, A., Ghirardelli, R.G.: Oral toxicity of the cyclic polyethers\u201412-crown-4, 15-crown-5, and 18-crown-6\u2014in mice. Tox. Appl. Pharmacol. 44, 263\u2013268 (1978)","journal-title":"Tox. Appl. Pharmacol."},{"key":"885_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1039\/b718962a","volume":"32","author":"AW Coleman","year":"2008","unstructured":"Coleman, A.W., Jebors, S., Cecillon, S., Perret, P., Garin, D., Marti-Battle, D., Moulin, M.: Toxicity and biodistribution of para-sulphonato-calix[4]arene in mice. New J. Chem. 32, 780\u2013782 (2008)","journal-title":"New J. Chem."},{"key":"885_CR21","unstructured":"Hwang, K.M., Qi, Y.M., Liu, S.Y., Lee, T.C., Choy, W., Chen, J.: Antithrombotic treatment with calix(n)arene compounds. Patent US 5409959 A; United States Genelabs Inc., 24 April 1995"},{"key":"885_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijpharm.2013.10.028","volume":"458","author":"EV Ukhatskaya","year":"2013","unstructured":"Ukhatskaya, E.V., Kurkov, S.V., Hj\u00e1lmarsd\u00f3ttir, M.A., Karginovd, V.A., Matthews, S.E., Rodik, R.V., Kalchenko, V.I., Loftsson, T.: Cationic quaternized aminocalix[4]arenes: cytotoxicity, haemolytic and antibacterial activities. Int. J. Pharm. 458, 25\u201330 (2013)","journal-title":"Int. J. Pharm."},{"key":"885_CR23","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1039\/b925555a","volume":"8","author":"VD Uzunova","year":"2010","unstructured":"Uzunova, V.D., Cullinane, C., Brix, K., Nau, W.M., Day, A.I.: Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study. Org. Biomol. Chem. 8, 2037\u20132042 (2010)","journal-title":"Org. Biomol. Chem."},{"key":"885_CR24","first-page":"536","volume":"112","author":"A Villiers","year":"1891","unstructured":"Villiers, A.: Sur la fermentation de la f\u00e9cule par l\u2019action du ferment butyrique. Compt. Rend. Acad. Sci. 112, 536\u2013538 (1891)","journal-title":"Compt. Rend. Acad. Sci."},{"key":"885_CR25","doi-asserted-by":"crossref","unstructured":"Hashimoto, H.: Aplication of Cyclodextrins to Foods, Toiletries and Other Products in Japan. In: Huber, O., Szejtli, J. (eds) Advances in Inclusion Science, Vol. 5: Proceedings of the Fourth International Symposium on Cyclodextrins, pp\u00a0533\u2013543. Kluwer Academic Publishers (1988)","DOI":"10.1007\/978-94-009-2637-0_76"},{"key":"885_CR26","first-page":"3","volume":"54","author":"World Health Organization","year":"2006","unstructured":"World Health Organization: Safety evaluation of certain food additives (\u03b1 cyclodextrin). 63rd meeting of the Joint FAO\/WHO Expert Committee on Food Additives (JECFA). WHO Food Addit. Ser. 54, 3\u201315 (2006)","journal-title":"WHO Food Addit. Ser."},{"key":"885_CR27","unstructured":"US Food and Drug Administration, Agency Response Letter Gras notice GRN No. 155, CFSAN (Center for Food Safety and Applied Nutrition)\/Office of Food Additive Safety (2004)"},{"key":"885_CR28","unstructured":"Food Standards Australia and New Zealand, Final Assessment Report, Application A494. Alpha-cyclodextrin as a novel food (2004)"},{"key":"885_CR29","first-page":"12","volume":"51","author":"European Commission","year":"2008","unstructured":"European Commission: 2008\/413\/EC: Commission Decision of 26 May 2008 authorising the placing on the market of alpha-cyclodextrin as a novel food ingredient under Regulation (EC) No 258\/97 of the European Parliament and of the Council. Off. J. Eur. Union 51, 12\u201315 (2008)","journal-title":"Off. J. Eur. Union"},{"key":"885_CR30","unstructured":"US Food and Drug Administration: Gras notice GRN No. 74. https:\/\/www.accessdata.fda.gov\/scripts\/fdcc\/?set=GRASNotices&id=74&sort=Substance&order=DESC&startrow=1&type=basic&search=418. (2001) Accessed 18 Oct 2018"},{"key":"885_CR31","first-page":"257","volume":"35","author":"World Health Organization","year":"1996","unstructured":"World Health Organization: Safety evaluation of certain food additives (\u03b2-cyclodextrin). Joint FAO\/WHO Expert Committee on Food Additives (JECFA). WHO Food Addit. Ser. 35, 257\u2013268 (1996)","journal-title":"WHO Food Addit. Ser."},{"key":"885_CR32","first-page":"969","volume":"44","author":"World Health Organization","year":"2000","unstructured":"World Health Organization: Safety evaluation of certain food additives (\u03b3-cyclodextrin). 53rd meeting of the Joint FAO\/WHO Expert Committee on Food Additives (JECFA). WHO Food Addit. Ser. 44, 969 (2000)","journal-title":"WHO Food Addit. Ser."},{"key":"885_CR33","unstructured":"US Food and Drug Administration, Agency Response Letter Gras notice GRN No. 46, CFSAN\/Office of Food Additive Safety (2000). http:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-foods-gen \/documents\/document\/ucm261675.pdf"},{"key":"885_CR34","unstructured":"Food Standards Australia and New Zealand, Final Assessment Report, Application A438: Gamma-cyclodextrin as a novel food (2003)"},{"key":"885_CR35","first-page":"41","volume":"55","author":"European Comission","year":"2012","unstructured":"European Comission: 2012\/288\/EU: Commission Implementing Decision of 1 June 2012, authorising the placing on the market of Gamma-Cyclodextrin as a novel food ingredient under Regulation (EC) No 258\/97 of the European Parliament and of the Council. Off. J. Eur. Comm. 55, 41\u201342 (2012)","journal-title":"Off. J. Eur. Comm."},{"key":"885_CR36","unstructured":"Vidal Vademecum Spain: Aerodiol solucion para pulverizacion nasal 150 \u00b5g\/dose (Espa\u00f1a). Vedemecum.es, https:\/\/www.vademecum.es\/equivalencia-lista-aerodiol+solucion+para+pulverizacion+nasal+150+%B5g%2Fdose-espana-g03ca03-es_1 (2018). Accessed 17 Oct 2018"},{"key":"885_CR37","unstructured":"Servier Laboratories (Aust) Pty Ltd: Aerodiol(R). Consumer Medicine Information (2007). http:\/\/www.medicines.org.au\/files\/secaerod.pdf Accessed 17 Oct 2018"},{"key":"885_CR38","unstructured":"TabletTree: Aerodiol Nasal Spray. TablerWise, https:\/\/www.tabletwise.com\/france\/aerodiol-nasal-spray (2018). Accessed 17 Oct 2018"},{"key":"885_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2958.2003.03975.x","volume":"52","author":"PW Denny","year":"2004","unstructured":"Denny, P.W., Goulding, D., Ferguson, M.A., Smith, D.F.: Sphingolipid free Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol. Microbiol. 52, 313\u2013327 (2004)","journal-title":"Mol. Microbiol."},{"key":"885_CR40","doi-asserted-by":"publisher","first-page":"44708","DOI":"10.1074\/jbc.M308063200","volume":"278","author":"R Zufferey","year":"2003","unstructured":"Zufferey, R., Allen, S., Barron, T., Sullivan, D.R., Denny, P.W., Almeida, I.C., Smith, D.F., Turco, S.J., Ferguson, M.A., Beverley, S.M.: Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J. Biol. Chem. 278, 44708\u201344718 (2003)","journal-title":"J. Biol. Chem."},{"key":"885_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pt.2006.12.003","volume":"23","author":"TJ Pucadyil","year":"2006","unstructured":"Pucadyil, T.J., Chattopadhyay, A.: Cholesterol: a potential therapeutic target in Leishmania infection? Trends Parasitol. 23, 49\u201353 (2006)","journal-title":"Trends Parasitol."},{"issue":"Pt 2","key":"885_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1042\/bj3350433","volume":"335","author":"S Ilangumaran","year":"1998","unstructured":"Ilangumaran, S., Hoessli, D.C.: Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem. J. 335(Pt 2), 433\u2013440 (1998)","journal-title":"Biochem. J."},{"key":"885_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10847-008-9510-9","volume":"63","author":"D Castagne","year":"2009","unstructured":"Castagne, D., Fillet, M., Delattre, L., Evrard, B., Nusgens, B., Piel, B.: Study of the cholesterol extraction capacity of \u03b2-cyclodextrin and its derivatives, relationships with their effects on endothelial cell viability and on membrane models. J. Incl. Phenom. Macrocycl. Chem. 63, 225\u2013231 (2009)","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"issue":"1","key":"885_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/A:1015861719134","volume":"8","author":"HW Frijlink","year":"1991","unstructured":"Frijlink, H.W., Eissens, A.C., Hefting, N.R., Poelstra, K., Lerk, C.F., Meijer, D.K.: The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res. 8(1), 9\u201316 (1991)","journal-title":"Pharm. Res."},{"key":"885_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.molbiopara.2003.10.002","volume":"133","author":"TJ Pucadyil","year":"2004","unstructured":"Pucadyil, T.J., Tewary, P., Madhubala, R., Chattopadhyay, A.: Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 133, 145\u2013152 (2004)","journal-title":"Mol. Biochem. Parasitol."},{"key":"885_CR46","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1462-5822.2006.00695.x","volume":"8","author":"NE Rodr\u00edguez","year":"2006","unstructured":"Rodr\u00edguez, N.E., Gaur, U., Wilson, M.E.: Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages. Cell. Microbiol. 8, 1106\u20131120 (2006)","journal-title":"Cell. Microbiol."},{"key":"885_CR47","unstructured":"Chattopadhyay, A., Madhubala, R.: Method of treating leishmaniasis using methylbeta-cyclodextrin, Patent U.S. 20050227944 A1, Counsil of Scientific and Industrial Research, 31 May 2005"},{"key":"885_CR48","unstructured":"European Medicines Agency, Background review for cyclodextrins used as excipients. EMA: (2014). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/12\/WC500177936.pdf Accessed 8 Nov 2018"},{"key":"885_CR49","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1128\/IAI.00214-13","volume":"81","author":"C Yao","year":"2013","unstructured":"Yao, C., Dixit, U.G., Barker, J.H., Teesch, L.M., Love-Homan, L., Donelson, J.E., Wilson, M.E.: Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion. Infect. Immun. 81, 2507\u20132517 (2013)","journal-title":"Infect. Immun."},{"key":"885_CR50","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1128\/AAC.05412-11","volume":"56","author":"X Zhu","year":"2012","unstructured":"Zhu, X., Pandharkar, T., Werbovetz, K.: Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimic. Agent Chemother. 56, 1182\u20131189 (2012)","journal-title":"Antimic. Agent Chemother."},{"key":"885_CR51","unstructured":"Drugbank. Meglumine antimoniate. Drugbank online database (2018). https:\/\/www.drugbank.ca\/drugs\/DB13732. Accessed 22 Dec 2018"},{"key":"885_CR52","first-page":"223","volume":"39","author":"PS Martins","year":"2009","unstructured":"Martins, P.S., Ribeiro, R.R., Bahia, A.P.C., Neto, R.L.M., Fr\u00e9zard, F.: Physicochemical characterization of orally-active meglumine antimoniate\/beta-cyclodextrin nanoassemblies: non-inclusion interactions and sustained drug release properties. Braz. J. Phys. 39, 223\u2013225 (2009)","journal-title":"Braz. J. Phys."},{"key":"885_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijpharm.2006.06.014","volume":"325","author":"PS Martins","year":"2006","unstructured":"Martins, P.S., Ochoa, R., Pimenta, A.M.C., Ferreira, L.A.M., Melo, A.L., da Silva, J.B.B., Sinisterra, R.D., Demicheli, C., Fr\u00e9zard, F.: Mode of action of \u03b2-cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. Int. J. Pharm. 325, 39\u201347 (2006)","journal-title":"Int. J. Pharm."},{"key":"885_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1128\/AAC.48.1.100-103.2004","volume":"48","author":"C Demicheli","year":"2004","unstructured":"Demicheli, C., Ochoa, R., da Silva, J.B.B., Falc\u00e3o, C.A.B., Rossi-Bergmann, B., Melo, A.L., Sinisterra, R.D., Fr\u00e9zard, F.: Oral delivery of meglumine antimoniate\u2013\u03b2-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agent Chemother. 48, 100\u2013103 (2004)","journal-title":"Antimicrob. Agent Chemother."},{"key":"885_CR55","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777X.62886","volume":"2","author":"S Sundar","year":"2010","unstructured":"Sundar, S., Chakravarty, J.: Liposomal amphotericin B and leishmaniasis: dose and response. J. Glob. Infect. Dis. 2, 159\u2013166 (2010)","journal-title":"J. Glob. Infect. Dis."},{"key":"885_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","volume":"248","author":"R Ghadi","year":"2017","unstructured":"Ghadi, R., Dand, N.: BCS class IV drugs: highly notorious candidates for formulation development. J. Control. Release 248, 71\u201395 (2017)","journal-title":"J. Control. Release"},{"key":"885_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0378-5173(86)90113-4","volume":"29","author":"N Rajagopalam","year":"1986","unstructured":"Rajagopalam, N., Chen, S.C., Chow, W.S.: A study of the inclusion complex of amphotericin B with \u03b3-cyclodextrin. Int. J. Pharm. 29, 161\u2013168 (1986)","journal-title":"Int. J. Pharm."},{"key":"885_CR58","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/bip.360280908","volume":"28","author":"M Kajt\u00e1r","year":"1989","unstructured":"Kajt\u00e1r, M., Vikmon, M., Morlin, E., Szejtli, J.: Aggregation of Amphotericin B in the presence of \u03b3-cyclodextrin. Biopolymers 28, 1585\u20131596 (1989)","journal-title":"Biopolymers"},{"key":"885_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijpharm.2014.07.004","volume":"473","author":"HK Ruiz","year":"2014","unstructured":"Ruiz, H.K., Serrano, D.R., Dea-Ayuela, M.A., Bilbao-Ramos, P.E., Bol\u00e1s-Fern\u00e1ndez, F., Torrado, J.J., Molero, G.: New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Int. J. Pharm. 473, 148\u2013157 (2014)","journal-title":"Int. J. Pharm."},{"key":"885_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/1381612023396258","volume":"8","author":"SL Croft","year":"2002","unstructured":"Croft, S.L., Yardley, V.: Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8, 319\u2013342 (2002)","journal-title":"Curr. Pharm. Des."},{"key":"885_CR61","unstructured":"Tocris Bioscience: Pentamidine isethionate. (2019). https:\/\/www.tocris.com\/products\/pentamidine-isethionate_3277#product-citations. Accessed 7 Jan 2019"},{"key":"885_CR62","unstructured":"U.S. National Library of Medicine: Pentamidine. ChemIDplus\u2014a toxnet database (2018). https:\/\/chem.nlm.nih.gov\/chemidplus\/rn\/100-33-4. Accessed 7 Jan 2019"},{"key":"885_CR63","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijpharm.2012.09.039","volume":"439","author":"EEB De Paula","year":"2012","unstructured":"De Paula, E.E.B., De Sousa, F.B., Silva, D., Fernandes, J.C., Melo, F.R., Fr\u00e9zard, M.N., Grazul, F., Sinisterra, R.M., Mechado, F.C.: Insights into the multi-equilibrium, superstructure system based on \u03b2-cyclodextrin and a highly water soluble guest. Int. J. Pharm. 439, 207\u2013215 (2012)","journal-title":"Int. J. Pharm."},{"key":"885_CR64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0250-474X.51958","volume":"71","author":"N Seedher","year":"2009","unstructured":"Seedher, N., Agarwal, P.: Various solvent systems for solubility enhancement of enrofloxacin. Indian J. Pharm. Sci. 71, 82\u201387 (2009)","journal-title":"Indian J. Pharm. Sci."},{"key":"885_CR65","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0731-7085(96)02033-X","volume":"15","author":"M Lizondo","year":"1997","unstructured":"Lizondo, M., Pons, M., Gallardo, M., Estelrich, J.: Physicochemical properties of enrofloxacin. J. Pharm. Biomed. Anal. 15, 1845\u20131849 (1997)","journal-title":"J. Pharm. Biomed. Anal."},{"key":"885_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14227\/DT220115P23","volume":"22","author":"GR Foresti","year":"2015","unstructured":"Foresti, G.R., Becker, N., Silva, A.S., Almeida, W.R.R., Malesuik, M.D., Hass, S.E., Silva, F.E.B.: An alternative method for the dissolution of enrofloxacin tablets. Dissolut. Techol. 22, 23\u201327 (2015)","journal-title":"Dissolut. Techol."},{"key":"885_CR67","unstructured":"Zadra, V.F., Custodio, C.C., Carvalho, M.A.S., Rodrigues-Carpentieri, L.N.: Binary inclusion complexes of enrofloxacin in 2-hydroxypropyl-\u03b2-cyclodextrin: preparation and characterization. World Small Animal Veterinary Association World Congress Proceedings. S\u00e3o Paulo, Brazil (2009). https:\/\/www.vin.com\/apputil\/content\/defaultadv1.aspx?id=4253100&pid=11290. Accessed 19 Nov 2018"},{"key":"885_CR68","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.biopha.2008.09.002","volume":"62","author":"NC Vieira","year":"2008","unstructured":"Vieira, N.C., Herrenknecht, C., Vacus, J., Fournet, A., Bories, C., Figad\u00e8re, B., Espindola, L.S., Loiseau, P.M.: Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomed. Pharmacother. 62, 684\u2013689 (2008)","journal-title":"Biomed. Pharmacother."},{"key":"885_CR69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biopha.2015.10.028","volume":"76","author":"K Balaraman","year":"2015","unstructured":"Balaraman, K., Vieira, N.C., Moussa, F., Vacus, J., Cojean, S., Pomel, S., Bories, C., Figad\u00e8re, B., Kesavan, V., Loiseau, P.M.: In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl \u03b2-cyclodextrin formulation and pharmacokinetics via intravenous route. Biomed. Pharmacother. 76, 127\u2013133 (2015)","journal-title":"Biomed. Pharmacother."},{"key":"885_CR70","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","volume":"57","author":"R Courtney","year":"2003","unstructured":"Courtney, R., Wexler, D., Radwanski, E., Lim, J., Laughlin, M.: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57, 218\u2013222 (2003)","journal-title":"Br. J. Clin. Pharmacol."},{"key":"885_CR71","unstructured":"National Center for Biotechnology Information, U.S. National Library of Medicine: Posoconazole. Compound Summary for CID 468595. PubChem (2019). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Posaconazole#section=Top. Accessed 9 Jan 2019"},{"key":"885_CR72","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ejps.2018.01.039","volume":"115","author":"B Hens","year":"2018","unstructured":"Hens, B., Bermejo, M., Tsume, Y., Gonzalez-Alvarez, I., Ruan, H., Matsui, K., Amidon, G.E., Cavanagh, K.L., Kuminek, G., Benninghoff, G., Fan, J., Rodr\u00edguez-Hornedo, N., Amidon, G.L.: Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach. Eur. J. Pharm. Sci. 115, 258\u2013269 (2018)","journal-title":"Eur. J. Pharm. Sci."},{"key":"885_CR73","unstructured":"Heimbecher, S.K., Monteith, D., Pipkin, J.D.: Posaconazole intravenous solution formulations stabilized by substituted \u03b2-cyclodextrin. Patent US9358297B2, Merck Sharp & Dohme Corp, 29 June 2010. https:\/\/patents.google.com\/patent\/US9358297B2\/en. Accessed 19 Nov 2018"},{"key":"885_CR74","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4269\/ajtmh.1983.32.947","volume":"32","author":"JD Bergman","year":"1983","unstructured":"Bergman, J.D., Lees, L.S.: Activity of oral drugs against Leishmania tropica in human macrophagues in vitro. Am. J. Trop. Med. Hyg. 32, 947\u2013951 (1983)","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"885_CR75","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/00034983.1988.11812275","volume":"82","author":"RA Neal","year":"1988","unstructured":"Neal, R.A., van Bueren, J., Hooper, G.: The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo. Ann. Trop. Med. Parasitol. 82, 453\u2013456 (1988)","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"885_CR76","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijantimicag.2014.07.011","volume":"44","author":"SR Passos","year":"2014","unstructured":"Passos, S.R., Rodrigues, T.A., Madureira, A.P., Giunchetti, R.C., Zanini, M.S.: Clinical treatment of cutaneous leishmaniasis in dogs with furazolidone and domperidone. Int. J. Antimic. Agent 44, 463\u2013465 (2014)","journal-title":"Int. J. Antimic. Agent"},{"key":"885_CR77","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/0035-9203(85)90358-X","volume":"79","author":"JML Costa","year":"1985","unstructured":"Costa, J.M.L., Sampaio, R.N., Tada, M.S., Almeida, E.A., Veiga, E.P., Magalhaes, A.V., Marsden, P.D.: Furazolidone treatment of cutaneous leishmaniasis. Trans. Royal Soc. Trop. Med. Hyg. 79, 274 (1985)","journal-title":"Trans. Royal Soc. Trop. Med. Hyg."},{"key":"885_CR78","unstructured":"U.S. National Library of Medicine: Furazolidone. ChemIDplus\u2014a toxnet database (2018). https:\/\/chem.nlm.nih.gov\/chemidplus\/rn\/67-45-8. Accessed 9 Jan 2019"},{"key":"885_CR79","doi-asserted-by":"publisher","first-page":"143153","DOI":"10.1016\/j.rvsc.2018.06.013","volume":"119","author":"SG Carvalho","year":"2018","unstructured":"Carvalho, S.G., Siqueira, L.A., Zanini, M.S., Matos, A.P.S., Quaresma, C.H., da Silva, L.M., de Andrade, S.F., Severi, J.A., Villanova, J.C.O.: Physicochemical and in vitro biological evaluations of furazolidone-based \u03b2-cyclodextrin complexes in Leishmania amazonensis. Res. Vet. Sci. 119, 143\u2013153 (2018)","journal-title":"Res. Vet. Sci."}],"container-title":["Journal of Inclusion Phenomena and Macrocyclic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10847-019-00885-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10847-019-00885-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10847-019-00885-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T20:41:20Z","timestamp":1610743280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10847-019-00885-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":79,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1007\/s10847-019-00885-y","relation":{},"ISSN":["1388-3127","1573-1111"],"issn-type":[{"type":"print","value":"1388-3127"},{"type":"electronic","value":"1573-1111"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"22 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}